Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I firmly believe in Bucillamine’s wider usage but candidly, I now believe little in Michael Frank as a leader to make Revive a success. I seriously hope I am proved wrong and challenge him to ensure I am and others are.
If MindMed can monetize this once regulated, investors will make millions. Holding my entire investment and adding when it makes sense for me.
Excellent step in the r$ght direction. Buying & Holding SHIB (large style).
MindMed Collaborators Announce Positive Topline Data from Phase 2 Trial of Lysergide (LSD) in Major Depressive Disorder (MDD):
Primary endpoint achieved statistically significant improvement in MDD symptoms
Confirmation of activity of lysergide in brain health disorders with direct relevance to MindMed’s MM-120 program in Generalized Anxiety Disorder (GAD)
Data presented on April 14, 2023 in Basel, Switzerland
NEW YORK, April 14, 2023 — Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, announced today that Prof. Matthias Liechti and Dr. Felix Mueller, MindMed collaborators at University Hospital Basel (UHB) and the University Hospital of Psychiatry, have released positive topline data from a double-blind, investigator-initiated trial evaluating lysergide in the treatment of MDD. These findings were presented on April 14, 2023 in Basel, Switzerland.
The topline data demonstrated significant, rapid, durable and beneficial effects of lysergide and its potential to mitigate symptoms of MDD. The high dose lysergide regimen in which patients received 100 µg at their first dosing day and 200 µg at their second dosing day (separated by four weeks) resulted in statistically and clinically significant improvements on the primary endpoint, which was the change in clinician-rated Inventory of Depressive Symptomatology (IDS-C) scores 6 weeks after the first administration as compared to control (whether or not the patient received a second administration). The control group in this study received a lower dose regimen of 25 µg on both treatment days. Patients in the high dose arm (n=28) demonstrated a least square mean change from baseline in IDS-C scores of -12.9 points compared to -3.6 points in the lower dose arm (n=27, p=0.02). The statistically significant benefit as measured by IDS-C was maintained up to 16 weeks after the first administration compared to placebo (p=0.008). Data from the secondary endpoints were also encouraging. The investigational drug was generally well-tolerated, as indicated by reported adverse events, changes in vital signs and laboratory values.
“We continue to be encouraged by the positive results being generated on the clinical activity of lysergide by our collaborators at UHB,” said Robert Barrow, Chief Executive Officer and Director of MindMed. “The statistically and clinically significant improvements observed in this study reinforce preliminary findings that have shown the clinical potential of lysergide in anxiety, depression and other brain health disorders. These positive findings are particularly relevant to our MM-120 program in generalized anxiety disorder, given the high degree of comorbidity of GAD and MDD. I would like to congratulate and thank our collaborators at UHB for once again generating high quality clinical data that continue to support the progression of our pipeline.”
Prof. Matthias Liechti, co-primary investigator of the trial, commented, “Historical studies of lysergide in MDD demonstrated rapid, robust and sustained improvement in depressive symptoms. We also observed improvement in depressive symptoms in patients with anxiety disorders in another of our recently published trials. We believed it was necessary to confirm the historical studies with ones using modern methods. Hence, we designed this randomized-controlled trial to assess the benefits of lysergide treatment in MDD. Importantly, an active small dose of lysergide was used as the control. We are extremely encouraged by the results we presented today, which demonstrate the strong, rapid and enduring improvements of this compound in patients suffering from MDD. We look forward to publishing the completed results in a peer-reviewed journal along with additional analyses. Our lab will continue investigating the therapeutic potential of lysergide and other psychedelics.”
About the Phase 2 Investigator-Initiated Clinical Trial
The investigator-initiated clinical trial was a double-blind, active-controlled, Phase 2 trial that investigated the safety and efficacy of lysergide for treating 61 patients with MDD. Patients allocated to the treatment intervention received 100 µg of lysergide on the first dosing day and 200 µg on the second dosing day, with dosing days separated by approximately 4 weeks. Patients allocated to the active control intervention received 25 µg of lysergide on the first dosing day and 25 µg of lysergide on the second dosing day. The primary efficacy endpoint was improvement in MDD symptoms six weeks after the first administration (2 weeks after the second administration), as measured by the clinician-rated Inventory of Depressive Symptomatology (IDS-C). Secondary outcome measures included improvements in the self-rated version of the Inventory of Depressive Symptomatology (IDS-SR), Beck Depression Index (BDI), State-trait anxiety inventory (STAI-G)) along with other psychiatric symptom assessments. Patients were followed for up to 16 weeks following the first dosing session. For additional information on this trial, see clinicaltrials.gov [NCT03866252].
MindMed supports the UHB Liechti Lab in conducting investigator-initiated trials for lysergide and other novel therapies and has exclusive access and rights to the data generated by these studies.
About MindMed
MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders.
MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.
Contacts
For Media & Investor Inquiries, please contact:
Maxim Jacobs, CFA
Vice President, Investor Relations and Corporate Communications
Mind Medicine (MindMed) Inc.
ir@mindmed.co
media@mindmed.co
Should expect a decent PPS rise here.
I don't think Frank will be surprised by the end part you reference CW. If anything it should place him under appropriate and merited pressure per se. If Frank gets emotional about it, it tells us a lot about him plus it would be him clutching at straws as part of a spineless attempt to disregard the letter.
I like and support this initiative put forth by the Reddit consortium. Frank needs to now stand up and be counted as his silence since early March is totally unacceptable and deeply alarming to most (serious) investors.
GL to us all (although luck is not a strategy of course..)
Wholeheartedly agree. Buying & holding DOGE big time.
Good stuff. Thank you.
What's the latest on the Reddit group initiative to have CEO Michael Frank respond to a series of shareholder questions? Anyone?
LMAbsoluteFAO @ “I think we should thank the CEO for trying” !!!!!!!!
WTF……………
BS. Buy them both, sit back and wait.
Disagree it is professional. Addressing shareholder sentiment and sharing the strategy/ action plan moving forward is not illegal. I have worked for public companies. IMO mf is an amateur.
Loading.
If it turns out CEO Michael Frank has ‘scammed’ us, a lawyer will offer little defense to the pound-of-flesh peeling that I sense he will experience having ruined so many families’ lives.
Just a hypothetical sense of course.
His silence is certainly deafening.
Where is his course of action follow-up to shareholders?
Amateur..
Big buy opportunity for me personally. The future appears very bright indeed.
Correct. Plus Bucillamine has many uses. That other poster your responded to just came back to gloat btw. Not worth your time.
Very encouraged moving forward.
Ecomike, you know I have valued many of your posts historically however, I disagree with your response here. That would represent an emotionally-backed stance and reeking of retaliation not to mention borderline vindictive by CEO MF.
CEO Michael Frank, like all good 'leaders' tend to do, should recognize investor sentiment after Monday's dire update and subsequent PPS plunge, and exercise some emotional intelligence at this point by addressing shareholders in a somewhat personalized manner - many of my CEO's do this and it proves effective at the best of times. MF and this whole FDA process has had us all sweating for going on 3 years now and the build-up has resulted in this current toilet-PPS.
Most of us Longs are looking at 80+% paper losses at present. MF needs to give us a status update / strategy to believe in. We merit that to say the least.
His silence stance appears both potentially dodgy and guilty in my opinion (mere speculation based on his action and I hope I am proved otherwise soon). Him communicating with us might effectively eliminate this sentiment, reduce the dumping and increase / encourage new investment.
If MF was confident about Bucillamine and Revive's future, he would and absolutely ought to be vocal about it.
I am an optimist by nature however, the crooked OTCM has screwed me left, right and center these past 18 months - 'hope' is no longer a strategy as an investor and based on his radio silence, hope is all MF is leaving us with currently.
CEO Michael Frank must address shareholders (at this alarming point). To not do so would be utterly spineless. And costly to all.
Thanks for the cheap shares peeps. #averagingdown.
Trip, us other Longs are all pissed too but please don't be THAT guy who sold everything on Monday and now lingers on here bashing it all. Based on your historic posts, you are classier than that I think.
Did you sell all your shares or have you held on to all / some, Trip?
If you are right about us being scammed, CEO Michael Frank should go into hiding. Seriously.
WTF. Numpty.
CEO Michael Frank, please address shareholders in a personalized note. Firmly believe this is wise and merited at this point. Many of us long term once continue to place considerable faith in you and are holding on with vast paper losses. Time-sensitive at this point I would say. Please give us at least a ‘team pep talk’.
Who else from the investor side agrees hearing from MF is more than appropriate at this time?
Not happy but not selling here either. CEO Michael Frank ought to personally address shareholders at this point. Only ever communicating in the form of news/update announcements is neither wise nor sound leadership.
Potentially so but personally I am done ‘believing’ in Kevin O’Leary’s influence.
He bailed on us with MindMed without announcing it plus truly how involved is he still here?
The former CEO of WonderFi proved utterly spineless by moving on before ‘success’ was achieved IMO.
Huge drop since I first invested.
Still invested in WonderFi but a bag holder at this point.
Sincere or sarcasm, Mike? Even if there is no update from the FDA, MF should exercise some true ‘leadership’ by communicating with his shareholders this evening no matter what.
Radio silence proves cancerous.
No comms whatsoever from CEO Michael Frank today is very, very poor form in my opinion.
Consider myself a strong advocate for Revive (plus a near 3 year investor) however, I am less than impressed with his total radio silence given the weeks of anticipation around March 7th.
I have said my piece.
Looking at the Trades on the iHub app on my phone, I see only x3 Sells vs a sea of green Buys. Unless you are referring to the past 15 mins or so (delay)? Or non-US side?
FDA verdict / update tomorrow. Last day ever at this low PPS all being well.
I would think any potential buy-out merits a $5B+ valuation. We shall know soon enough.
Go on then..enlighten us with the justified rational (in detail) behind your bold claim, Nostradamus. You honestly can't can you? Then back to the basement couch for you pal.
uh? No, I just think (know) you are a c#nt. Get over yourself you sad little twat.
I'm buying more here not running you insolent little peasant.
Turd on a string you are (based on your posts). Pucker up and be patient and/or at least silent son surely?
Adding 8.2B SHIB. An easy choice given my DD.
How many are you adding / buying? Not a pissing contest..this is sincere intrigue and an comrade attempt at further understanding a widespread retail investor sentiment (given all that is in the pipeline for Shiba Inu).
Great stuff!
This is an easy investment moving forward.
I wholeheartedly believe in this investment too. Kick back and watch the show.